Abstract
The number of individuals afflicted by Alzheimer’s disease (AD) worldwide is rapidly rising and we, as a society, are approaching a critical junction in the development of new therapeutics aimed at slowing or preventing the onset of this devastating neurodegenerative disease. The prevailing theory in the field pinpoints the amyloid β peptide (Aβ) as the causal agent of the disease and thus strategies that target the production, deposition, and clearance of Aβ in the brain continue to be at the forefront of therapeutic interventions. Aβ is produced through a series of proteolytic cleavage events, with β-secretase (BACE1) being the rate-limiting enzymatic activity needed to begin the liberation of the Aβ peptide from the larger amyloid precursor protein (APP). As such, BACE1 itself has become a prime therapeutic target for AD. Still, over ten years after its discovery, only a handful of compounds targeting BACE1 have reached clinical trial, indicating that complex challenges continue to persist. This short review will focus on the cellular and molecular characteristics of BACE1, its role in APP processing and in AD, and its potential as a therapeutic target for AD.
Keywords: Alzheimer’s Disease, amyloid β-Peptide, β-Secretase, BACE1, therapeutics.
Current Enzyme Inhibition
Title:BACE1: Expression, Regulation, and Therapeutic Potential of the Major Alzheimer’s Disease Beta-Secretase
Volume: 9 Issue: 1
Author(s): Christopher J. Holler and Michael P. Murphy
Affiliation:
Keywords: Alzheimer’s Disease, amyloid β-Peptide, β-Secretase, BACE1, therapeutics.
Abstract: The number of individuals afflicted by Alzheimer’s disease (AD) worldwide is rapidly rising and we, as a society, are approaching a critical junction in the development of new therapeutics aimed at slowing or preventing the onset of this devastating neurodegenerative disease. The prevailing theory in the field pinpoints the amyloid β peptide (Aβ) as the causal agent of the disease and thus strategies that target the production, deposition, and clearance of Aβ in the brain continue to be at the forefront of therapeutic interventions. Aβ is produced through a series of proteolytic cleavage events, with β-secretase (BACE1) being the rate-limiting enzymatic activity needed to begin the liberation of the Aβ peptide from the larger amyloid precursor protein (APP). As such, BACE1 itself has become a prime therapeutic target for AD. Still, over ten years after its discovery, only a handful of compounds targeting BACE1 have reached clinical trial, indicating that complex challenges continue to persist. This short review will focus on the cellular and molecular characteristics of BACE1, its role in APP processing and in AD, and its potential as a therapeutic target for AD.
Export Options
About this article
Cite this article as:
J. Holler Christopher and P. Murphy Michael, BACE1: Expression, Regulation, and Therapeutic Potential of the Major Alzheimer’s Disease Beta-Secretase, Current Enzyme Inhibition 2013; 9 (1) . https://dx.doi.org/10.2174/1573408011309010003
DOI https://dx.doi.org/10.2174/1573408011309010003 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Hypoxia Inducible Factor-1 as a Therapeutic Target in Cerebral Ischemia
Current Signal Transduction Therapy Hypoxic Preconditioning Increases Blood-Brain Barrier Disruption in the Early Stages of Cerebral Ischemia
Current Neurovascular Research New Insights in Mast Cell Modulation by Palmitoylethanolamide
CNS & Neurological Disorders - Drug Targets Alcohol Related Changes in Regulation of NMDA Receptor Functions
Current Neuropharmacology Immunomodulatory Therapy Associated to Anti-Parasite Drugs as a Way to Prevent Severe Forms of Malaria
Current Clinical Pharmacology A Brief Review of Cardiovascular Diseases, Associated Risk Factors and Current Treatment Regimes
Current Pharmaceutical Design Transcription Factors as Therapeutic Targets in CNS Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Fetal Programming of the Human Brain: Is there a Link with Insurgence of Neurodegenerative Disorders in Adulthood?
Current Medicinal Chemistry Subject Index To Volume 12
Current Pharmaceutical Design Neural Stem Cells as Biological Minipumps: A Faster Route to Cell Therapy for the CNS?
Current Stem Cell Research & Therapy Matrix Metalloproteinases as Valid Clinical Target
Current Pharmaceutical Design Microdialysis in Neurointensive Care
Current Pharmaceutical Design Medico-Legal Evaluation of Fatal Perinatal Asphyxia
Current Pediatric Reviews Why and How We Should Treat Elderly Patients with Hypertension?
Current Vascular Pharmacology Lipid Matrix Nanoparticles: Pharmacokinetics and Biopharmaceutics
Current Nanoscience Recent Patents, Regulatory Issues, and Toxicity of Nanoparticles in Neuronal Disorders
Current Drug Metabolism Hormonal Effects on Drug Metabolism Through the CYP System: Perspectives on Their Potential Significance in the Era of Pharmacogenomics
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Neuroprotection & Mechanism of Ethanol in Stroke and Traumatic Brain Injury Therapy: New Prospects for an Ancient Drug
Current Drug Targets Candidate Susceptibility Genes in Alzheimers Disease Are at High Risk for Being Forgotten - They Dont Give Peace of Mind...
Current Drug Metabolism Advances in Anti-inflammatory Activity, Mechanism and Therapeutic Application of Ursolic Acid
Mini-Reviews in Medicinal Chemistry